The short answer.
BHRT dosing is personalized by integrating baseline labs, symptom presentation, age, medical history, and treatment goals into a conservative starting dose. Follow-up labs at 8-12 weeks confirm whether levels are tracking and surface unintended effects. Dose is adjusted based on both biomarker movement and clinical response. Personalization is continuous across visits, not a one-shot calibration.
The clinical detail.
"Personalized BHRT" gets used loosely. The clinical meaning is: dose, route, frequency, and adjunct medications are selected based on this patient's biology — baseline labs, symptom rubric, age, body composition, medical history, medication list, and lifestyle context — rather than based on a fixed protocol or population average. Personalization is a method, not a product.
What we use to personalize the starting dose.
Before initiating BHRT we gather four streams of input:
- Baseline labs. For women: estradiol, progesterone, FSH, LH, free and total testosterone, SHBG, DHEA-S, full thyroid panel, cortisol assessment, metabolic and inflammatory context (HbA1c, lipids, hsCRP, vitamin D, ferritin, CBC). For men: total and free testosterone, SHBG, estradiol, LH, FSH, DHEA-S, prolactin, thyroid, PSA, plus the same metabolic context.
- Structured symptom rubric. Not "how do you feel" — specific scoring across sleep, energy, mood, libido, recovery, cognition, body composition, and any sex-specific symptoms. This is the qualitative complement to the labs.
- Medical and medication history. Prior hormone use, current medications and supplements, comorbidities, surgical history, family cancer history, thrombotic history, prior reactions to medications.
- Goals and constraints. What does the patient want to feel like? What are they trying to fix? Are they preserving fertility? Are they planning future pregnancy? Are they on a fixed-cost budget? Do they prefer daily dosing or pellets?
From these inputs we select a conservative starting dose. Conservative is the operating principle — it's easier to titrate up than to back out a dose that produced side effects. Starting dose ranges depend on the hormone, route, and patient:
- Testosterone for men: 80-120 mg/week injectable, or equivalent topical dose, depending on baseline total and free testosterone, SHBG, age, body composition.
- Estradiol for women: typically lowest commercial patch or 0.025-0.5 mg cream once or twice daily, depending on symptoms, age, time since menopause, prior tolerance.
- Progesterone for women with uterus: 100-200 mg micronized progesterone at bedtime, sometimes cycled depending on cycle status.
- Testosterone for women: 2-5 mg/day topical cream or pellet equivalent.
- Thyroid replacement: T3-containing combination products or T4 only, dose-titrated against TSH, free T3, free T4, reverse T3, and symptoms.
What happens at the 8-12 week follow-up.
This visit is the central personalization gate. We re-test the same panel we drew at baseline, focusing on the markers most likely to have shifted. The follow-up data tells us four things:
- Did the hormone reach its target range? If testosterone is still subtherapeutic, dose increase is indicated. If estradiol is supratherapeutic, dose reduction is indicated.
- Are there unintended effects? Rising hematocrit on testosterone, off-target estradiol in men, thyroid suppression on certain hormone protocols, breakthrough bleeding in women.
- How do the symptoms compare to baseline? Symptom rubric is repeated at this visit. Sleep improvement, energy, libido, mood, recovery — quantified comparison.
- What's drifted in the metabolic/inflammatory context? Lipids, glucose, hsCRP. Hormone therapy can shift these, and the shift is part of the personalization picture.
Based on this data, we adjust the protocol: dose, frequency, route, or addition/removal of adjuncts (anastrozole for elevated estradiol on testosterone, finasteride in selected cases, hCG, low-dose thyroid, etc.). The adjustment is then re-evaluated at the next interval.
Personalization across the longer arc.
Personalization doesn't end at month 3. The body changes. Life context changes. Other variables enter and exit. We expect to make protocol adjustments over time:
- A woman's needs shift as she moves from perimenopause through menopause into stable postmenopausal physiology — dose typically decreases over time as endogenous oscillations settle.
- A man on TRT may need dose adjustment as body composition changes (more lean mass = higher dose tolerance; weight gain = more aromatization to estradiol).
- Major life events (illness, surgery, stress periods, training cycle changes) can shift the optimal dose temporarily or durably.
- Concomitant medication changes can shift hormone clearance or interact with hormone signaling.
This is why we re-test every 6 months for stable patients and run a comprehensive annual draw. Personalization is the discipline of staying close to what each patient currently needs — not the discipline of selecting a clever protocol on day 1 and walking away.
Where this fits in our methodology.
The CLARITY methodology is built around this continuous-personalization principle. Every visit is a re-personalization checkpoint. The patient's protocol is not a fixed product they bought; it's a clinical state that gets re-derived at each touchpoint from current data. See the methodology in full.
For more on BHRT itself, see the BHRT service page. For broader hormone-therapy context, see the Hormone Therapy FAQ.